Urolithin A Blocks Inflammatory Aging Signals by Targeting DNA Leakage in Senescent Cells

Cellular senescence drives aging and age-related diseases through the release of inflammatory factors called SASP (senescence-associated secretory phenotype) and DAMPs (damage-associated molecular patterns). Current senomorphic drugs that target these pathways often have broad effects that can impair normal immune responses, limiting their therapeutic potential.

Researchers investigated urolithin A (UA), a metabolite produced by gut bacteria from ellagitannins found in pomegranates, berries, and nuts. Using human fibroblast cells, they induced senescence through doxorubicin treatment and replicative exhaustion, then tested UA's effects on inflammatory signaling.

The key discovery was that UA significantly reduces cytosolic DNA leakage in senescent cells. Normally, damaged senescent cells release DNA fragments into their cytoplasm, which triggers the cGAS-STING pathway - an evolutionary pathogen detection system. This cascade activates transcription factors NF-κB and IRF3, driving production of inflammatory cytokines. UA treatment reduced this DNA leakage by 40-50% and correspondingly decreased STING phosphorylation.

Consequently, UA treatment led to significant reductions in key inflammatory factors: IL-6, IL-8, and IL-1α expression dropped substantially in both senescence models. Importantly, conditioned media from UA-treated senescent cells caused 60% fewer neighboring cells to become senescent, demonstrating UA's ability to break the cycle of paracrine senescence spread.

The clinical implications are promising. Unlike broad anti-inflammatory drugs, UA appears to specifically target the aberrant DNA sensing that drives pathological inflammation in senescent cells while preserving normal immune function. Previous studies have shown UA improves muscle function in older adults and reduces inflammation in aged mice, supporting its therapeutic potential for healthy aging interventions.